1 / 22

Healthcare Sector Stock Presentation

Healthcare Sector Stock Presentation. Winter 2006 Xin Lu Hai-ran Xu. Agenda. Sector and Current Holding Recommendations Business Analysis Financial Analysis Valuation Analysis Conclusions Q&A. Sector and Current Holding. Defensive Sector Demographics-driven Prospect

ramona-harmon
Download Presentation

Healthcare Sector Stock Presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Healthcare SectorStock Presentation Winter 2006 Xin Lu Hai-ran Xu

  2. Agenda • Sector and Current Holding • Recommendations • Business Analysis • Financial Analysis • Valuation Analysis • Conclusions • Q&A

  3. Sector and Current Holding • Defensive Sector • Demographics-driven Prospect • Heavily Regulated • High Entry Barrier, Little Substitute • Vulnerable to Legal Cost • Generic Drug Impact

  4. Current Holding • Current Holding: • BSX = 2.32% • JNJ = 3.41% • MRK = 5.64% • UNH = 1.11% • PFE = 3.72% SIM percentage = 16.20% S&P percentage = 13.58% • We voted to maintain current weight

  5. Recommendations • Pfizer (PFE): BUY by 110 basis point • United Health Group (UNH): SELL by 110 basis point

  6. Pfizer-Business Analysis • Largest Drug Manufacturer • Strong R&D and Marketing • Wide Product Lines • Won Patent Cases • Blockbuster Lipitor hurt by Zocor • Generous Dividend and Stock Buy-back • Spun off its Consumer Product Division to boost growth

  7. Pfizer-Financial Analysis • Sales growth slowed down

  8. Pfizer-Financial Analysis • Volatile Before-tax Margin

  9. Pfizer-Financial Analysis • ROE

  10. Pfizer-Valuation • Current Price: $26.37 • Cost: $30.57 • Shares: 745,157

  11. Pfizer-Valuation It is Cheap!!!

  12. Pfizer-Valuation • DCF Assumptions: • Sales growth at 3% to perpetuity • EBIT at 28% • Tax rate at 30% • Discount rate 9% (4.58%+0.5*6%) • Current Financial Structure • No M&A or Spin-off

  13. Pfizer-Recommendation • Target Price $31.64

  14. United Health Group-Business Analysis • Health care plan industry • Three business units • UnitedHealthcare • mid-size local employers and consumers • AmeriChoice • State medical programs • Ovations • Health service to American over the age of 50

  15. United Health Group-Business Analysis • UNH business will go to mature • In 2005 10-K report • UnitedHealthcare increase 24% (15% from M&A) • AmeriChoice 9% (all from M&A) • Ovations 24% (4% from M&A) • Growth expectation of UnitedHealthcare and AmeriChoice would be lower in 2006

  16. United Health Group-Financial Analysis

  17. United Health Group-Financial Analysis

  18. United Health Group-Valuation Analysis

  19. United Health Group-Valuation Analysis

  20. United Health Group-recommendations • Sell at Current Price $58.89 • 52 weeks high $64.61 By the way, CEO of UNH sold stocks in February

  21. Conclusion +/- Target % Current % +1.11% 4.83% 3.72% PFE • Cheap Stock • Demographics Drive Long-term Performance • Restructuring Boost Margin • Aggressive Buy-back and Generous Dividend UNH 1.11% -1.11% - • Relatively Expensive Stock • Mature Business with Low Growth • Management Sells Stock

  22. Thank You! Q & A It is time to wake up

More Related